Drugs / vNKT cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05783076 | Jun 2023 → Mar 2024 | malignant pancreatic neoplasm | Changhai Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vNKT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05783076 ↗ |
| Action | Deplete | “This CD8+ NKT cells has more potent anti-tumor effects than conventional T and NK cells, which is manifested by killing tumor cells and myeloid derived suppressor cells.” NCT05783076 ↗ |
| Modality | Cell therapy | “The aim of this study is to evaluate the efficacy and safety of SBRT plus vNKT cells as adoptive cell therapy for advanced pancreatic cancer.” PMID 40671381 ↗ Jul 2025 |
| Route | Other | “vNKT cells should be transfused into patients within 24 hours.” NCT05783076 ↗ |